PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1742848
PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1742848
Global Aortic Endografts Market to Reach US$3.6 Billion by 2030
The global market for Aortic Endografts estimated at US$2.9 Billion in the year 2024, is expected to reach US$3.6 Billion by 2030, growing at a CAGR of 3.7% over the analysis period 2024-2030. Abdominal Aortic Grafts, one of the segments analyzed in the report, is expected to record a 3.1% CAGR and reach US$2.4 Billion by the end of the analysis period. Growth in the Thoracic Aortic Grafts segment is estimated at 5.1% CAGR over the analysis period.
The U.S. Market is Estimated at US$796.1 Million While China is Forecast to Grow at 6.8% CAGR
The Aortic Endografts market in the U.S. is estimated at US$796.1 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$728.5 Million by the year 2030 trailing a CAGR of 6.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.5% and 2.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.1% CAGR.
Global Aortic Endografts Market - Key Trends & Drivers Summarized
Why Are Aortic Endografts Redefining the Standard of Care in Aneurysm Repair and Vascular Disease Management?
Aortic endografts-used in endovascular aneurysm repair (EVAR) and thoracic endovascular aortic repair (TEVAR)-have revolutionized the treatment of aortic aneurysms by enabling minimally invasive interventions that significantly reduce perioperative risk, hospital stay, and recovery time. These graft-stent hybrids are deployed inside the aorta to exclude aneurysmal sacs from blood flow, preventing rupture while preserving vascular continuity. Their use has become central in managing abdominal aortic aneurysms (AAA) and thoracic aortic aneurysms (TAA), especially in high-risk or elderly patients who are not ideal candidates for open surgical repair.
The transition from open surgery to EVAR and TEVAR is supported by strong clinical outcomes, including lower procedural mortality, reduced postoperative complications, and faster patient mobilization. Aortic endografts are increasingly being used in both elective and emergency settings, including ruptured aneurysms and traumatic aortic injuries, underscoring their growing relevance in acute vascular care. Their precision-engineered architecture-comprising self-expanding metallic stents and biocompatible graft fabrics-enables tailored solutions for complex anatomies and challenging vascular access pathways.
Beyond aneurysm exclusion, aortic endografts are gaining traction in hybrid and branched endovascular procedures for aortic dissections, penetrating atherosclerotic ulcers, and other pathologies involving the thoracic and abdominal aorta. These expanded indications, along with supportive clinical data and evolving surgical expertise, are driving greater adoption among vascular surgeons and interventional radiologists. As patient selection broadens and device versatility improves, aortic endografts are redefining therapeutic possibilities in vascular medicine.
How Are Device Design Innovations and Imaging Integration Enhancing Procedural Precision and Outcomes?
Advancements in device design are transforming aortic endografts into highly customizable, anatomy-conforming implants that accommodate wide variations in aortic diameter, tortuosity, and branch vessel proximity. Modular graft systems, low-profile delivery sheaths, and repositionable stent components are improving navigation through narrow or calcified iliac arteries, enabling safe deployment even in patients with hostile anatomies. The integration of suprarenal fixation, active sealing rings, and fenestrated or branched designs is extending applicability to juxtarenal and thoracoabdominal aneurysms previously considered unsuitable for EVAR or TEVAR.
The role of imaging has become integral to the success of aortic endograft placement. High-resolution preoperative CT angiography, 3D vascular mapping, and intraoperative fluoroscopy or cone-beam CT enable precise device sizing, landing zone identification, and real-time graft navigation. Advanced fusion imaging platforms now offer dynamic guidance by overlaying pre-op scans onto live angiographic views, significantly reducing contrast use, radiation exposure, and operative time. These tools are helping operators achieve optimal sealing and alignment, while minimizing endoleak risk and procedural complications.
Material innovation is further enhancing graft durability and biocompatibility. Improvements in graft fabrics, such as woven polyester and ePTFE with heparin-bonded surfaces, are improving thromboresistance, minimizing inflammatory response, and extending implant longevity. Long-term performance is being closely linked to material fatigue resistance, radial strength, and conformability, especially in younger or more active patients. As device technology advances, the focus is shifting toward reducing reintervention rates and improving long-term clinical durability of endograft therapy.
Which Clinical Indications and Regional Markets Are Driving Growth in Aortic Endograft Adoption?
The most common indication for aortic endograft use remains abdominal aortic aneurysm (AAA) repair, where EVAR has become the standard of care in many high-income markets. Thoracic aortic aneurysm (TAA) repair using TEVAR is also gaining adoption, especially for descending aorta involvement and aortic arch extension cases requiring complex branched grafts. Additional clinical indications include traumatic aortic transections, chronic type B dissections, and hybrid repairs in multilevel aortic disease-broadening procedural volumes and device utilization across vascular specialties.
Demand is particularly strong in countries with aging populations, high cardiovascular disease prevalence, and advanced hospital infrastructure. North America and Western Europe are mature markets with high procedural penetration, sustained by favorable reimbursement policies, robust screening programs, and specialist surgical training. Meanwhile, Asia-Pacific is witnessing accelerated growth due to rising awareness, expanding vascular programs, and infrastructure upgrades in China, India, South Korea, and Japan. Latin America and Eastern Europe are also increasing adoption through government-funded cardiac and vascular care expansion initiatives.
Public health policies that emphasize early aneurysm screening, especially among men aged 65 and older, are reinforcing demand in developed countries. In parallel, private healthcare networks and specialty hospitals in emerging markets are investing in endovascular capabilities to attract high-value cardiovascular procedures. As health systems prioritize minimally invasive care, short inpatient stays, and outcome-based reimbursement, aortic endografts are increasingly positioned as the preferred option in aneurysm repair and vascular trauma response.
How Are Regulatory Trends, Competitive Differentiation, and Post-Market Surveillance Influencing the Market Landscape?
Regulatory authorities are refining approval pathways and surveillance protocols for aortic endografts to ensure both procedural safety and long-term device performance. In major markets, regulatory frameworks now require robust evidence of durability, anatomical compatibility, and procedural reproducibility. Post-market surveillance programs-including device registries, mandatory follow-up imaging, and adverse event reporting-are shaping product lifecycle management and manufacturer accountability.
Manufacturers are differentiating through innovations in graft design, delivery system ergonomics, and endoleak mitigation strategies. Competitive positioning is being driven by ease of deployment, anatomical versatility, and device compatibility with hybrid and branched configurations. Some players are offering physician-modifiable or off-the-shelf branched endografts to reduce manufacturing lead times and improve emergency use readiness. Strategic partnerships with imaging companies and training institutions are enhancing brand loyalty and procedural standardization.
With greater focus on outcomes and cost-effectiveness, value-based procurement models are emerging in several healthcare systems. Hospitals and payers are evaluating aortic endografts not only by their unit cost but by total treatment cost, including reintervention rates, long-term durability, and imaging burden. As healthcare delivery moves toward precision medicine and real-time procedural support, devices that integrate smart feedback, imaging compatibility, and adaptive deployment will command a premium in the competitive landscape.
What Are the Factors Driving Growth in the Aortic Endografts Market?
The aortic endografts market is expanding steadily, driven by a confluence of clinical demand, technological advancement, and health system preferences for minimally invasive therapies. The growing burden of aortic aneurysms, improvements in vascular diagnostics, and continued migration from open surgery to EVAR and TEVAR procedures are core market drivers. Key growth enablers include the rising incidence of vascular trauma, aging demographics, and expanded indications for endovascular repair in complex and urgent cases.
Ongoing device innovation, integration with advanced imaging, and enhanced physician training are accelerating procedural adoption across both developed and emerging healthcare systems. Strategic investments in hybrid ORs, vascular centers of excellence, and multidisciplinary care models are reinforcing institutional readiness for endograft-based interventions. Market expansion is further supported by streamlined regulatory approvals and targeted reimbursement policies that recognize the clinical and economic value of minimally invasive vascular repair.
Looking ahead, the trajectory of the aortic endografts market will be shaped by how effectively device platforms address anatomical complexity, long-term durability, and procedure-specific customization. As endovascular care continues to evolve, could aortic endografts emerge as the definitive cornerstone of 21st-century aortic disease management?
SCOPE OF STUDY:
The report analyzes the Aortic Endografts market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Product Type (Abdominal Aortic Grafts, Thoracic Aortic Grafts); Material (Metallic Endografts, Polymeric Endografts); End-Use (Hospitals, Ambulatory Surgery Centers, Other End-Uses)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Select Competitors (Total 41 Featured) -
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.
We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.
As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.
To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!
APRIL 2025: NEGOTIATION PHASE
Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.
JULY 2025 FINAL TARIFF RESET
Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.
Reciprocal and Bilateral Trade & Tariff Impact Analyses:
USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.
Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.
COMPLIMENTARY PREVIEW
Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.